A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

This study is testing a new oral medication called AVZO-021, which is designed to block a specific protein that helps cancer cells grow. By evaluating this drug alone or combined with other therapies, researchers hope to find new, effective ways to treat various types of advanced cancers.

This trial is looking for adults aged 18 or older with specific types of advanced cancers, including certain breast, ovarian, and uterine cancers. Participants generally need to have a specific genetic change called CCNE1, or have seen their cancer continue to grow despite trying standard treatment options.

You will receive the study drug, AVZO-021, and undergo regular check-ups to monitor how your body reacts and how the cancer responds to the treatment. The medical team will track your health closely to ensure the treatment is safe and to determine the best dose for patients.

The study is currently recruiting patients at research centers in New Haven, Connecticut, and Sarasota and Tampa, Florida. Please speak with your doctor to see if one of these locations is an option for you.